Drugs / pep2dia
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06452511 Comparator | Aug 2024 → Mar 2025 | polycystic ovary syndrome | Muhamed Ahmed Abdelmoaty Muhamed Alhagrasy | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pep2dia | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06452511 ↗ |
| Modality | Peptide | “Pep2dia, a peptide-based therapy tailored to manage PCOS” NCT06452511 ↗ |